1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassium salt
Modify Date: 2024-01-29 23:59:08
1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassium salt structure
|
Common Name | 1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassium salt | ||
|---|---|---|---|---|
| CAS Number | 157124-84-0 | Molecular Weight | 500.63 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C16H16K3O7PS | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 1-phosphono-4-(3-phenoxyphenyl) butylsulfonic acid tripotassium saltBPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation)[1]. |
| Name | BPH-652 |
|---|
| Description | BPH-652 is a S. aureus dehydrosqualene synthase (CrtM) inhibitor, with a Ki of 1.5 nM and an IC50 of 100-300 nM (S. aureus pigment formation)[1]. |
|---|---|
| Related Catalog | |
| Target |
Ki: 1.5 nM (CrtM). IC50: 100-300 nM (S. aureus pigment formation)[1]. |
| In Vivo | BPH-652 treatment (0.5 mg twice per day (days −1, 0, 1, and 2), Intraperitoneal injection) significantly lowers S. aureus bacterial counts in the kidneys of the mice than those of the control group (P < 0.001), with 8 of 13 below the detection threshold, versus only 2 of 14 in the control group; on average, this result corresponds to a 98% decrease in surviving bacteria in the treatment group[1]. Animal Model: A systemic S. aureus infection model in mice[1]. Dosage: 0.5 mg twice per day (days −1, 0, 1, and 2). Administration: Intraperitoneal injection. Result: S. aureus bacterial counts in the kidneys of the mice treated with BPH-652 were significantly lower than those of the control group. |
| References |
| Molecular Formula | C16H16K3O7PS |
|---|---|
| Molecular Weight | 500.63 |